Pinz and colleagues demonstrated that modified CD8+ T cells expressing CD4 CAR induced robust anti-tumor effects in vivo, and CAMPATH was used as a natural safety switch to prevent unwanted toxicities [43, 46]. Here, CD8A is linked to neoplasm.